A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

NCT03978520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

341

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: Elsubrutinib
DRUG: Placebo for elsubrutinib
DRUG: Upadacitinib
DRUG: Placebo for upadacitinib

Sponsor

AbbVie